Drug name - Promacta Kit
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7160870 | NOVARTIS | Thrombopoietin mimetics |
Nov, 2022
(a month from now) | |
| US7547719 | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jul, 2025
(2 years from now) | |
| CN101343250A | NOVARTIS | Thrombopoietin Mimics |
May, 2020
(2 years ago) | |
| CN101343251B | NOVARTIS | Thrombopoietin Mimetics |
May, 2020
(2 years ago) | |
| CN101343250B | NOVARTIS | Thrombopoietin Mimetics |
May, 2020
(2 years ago) | |
| CN101343251A | NOVARTIS | Thrombopoietin Mimetics |
May, 2020
(2 years ago) | |
| CN100423721C | NOVARTIS | Thrombopoietin Mimetics |
May, 2021
(1 year, 4 months ago) | |
| CN1444477A | NOVARTIS | Thrombopoietin Mimetics |
May, 2021
(1 year, 4 months ago) | |
| CN100542530C | NOVARTIS | 3 '-[(2Z)-[3 - (1, 4-Dimethylphenyl) 1, 5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4] Hydrazino] 2 ' - Hydroxy - [1 1 ' - Biphenyl] - 3-Di - (Monoethanolamine) |
May, 2023
(7 months from now) | |
| CN1652842A | NOVARTIS | 3 '-[(2Z)-[3 - (1, 4-Dimethyl-Phenyl)--1, 5-Dihydro - -3 - Methyl - -5 - Oxo - -4H - Pyrazol - -4 - Pyrazol-4-Ylidene] Hydrazino] -2 ' - Hydroxy - [1 1 ' - Biphenyl]--3 - Di - (Monoethanolamine) |
May, 2023
(7 months from now) | |
| IN200201666P3 | NOVARTIS | A Compound And A Pharmaceutical Composition For Use In Enhancing Platelet Production |
May, 2021
(1 year, 4 months ago) | |
| IN213176B | NOVARTIS | A Compound And A Pharmaceutical Composition For Use In Enhancing Platelet Production |
May, 2021
(1 year, 4 months ago) | |
| IN200403400P1 | NOVARTIS | 3'-[(2Z)-[1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene]Hydrazino]-2'-Hydroxy-[1,2'-Biphenyl]-3-Carboxylic Acid Bis-(Monoethanolamine) |
May, 2023
(7 months from now) | |
| IN233161B | NOVARTIS | 3'-[(2Z)-[1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene]Hydrazino]-2'-Hydroxy-[1,1'-Biphenyl]-3-Carboxylic Acid Bis-(Monoethanolamine) |
May, 2023
(7 months from now) | |
| EP1889838B1 | NOVARTIS | Thrombopoietin Mimetics |
May, 2021
(1 year, 4 months ago) | |
| EP1889838A1 | NOVARTIS | Thrombopoietin Mimetics |
May, 2021
(1 year, 4 months ago) | |
| EP1864981A1 | NOVARTIS | Thrombopoietin Mimetics |
May, 2021
(1 year, 4 months ago) | |
| EP1864981B1 | NOVARTIS | Thrombopoietin Mimetics |
May, 2021
(1 year, 4 months ago) | |
| EP1864981B8 | NOVARTIS | Thrombopoietin Mimetics |
May, 2021
(1 year, 4 months ago) | |
| EP1534390B1 | NOVARTIS | 3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine) |
May, 2023
(7 months from now) | |
| EP1534390A2 | NOVARTIS | 3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine) |
May, 2023
(7 months from now) | |
| EP1534390A4 | NOVARTIS | 3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine) |
May, 2023
(7 months from now) | |
| EP1294378A2 | NOVARTIS | Thrombopoietin Mimetics |
Mar, 2025
(2 years from now) | |
| EP1294378B1 | NOVARTIS | Thrombopoietin Mimetics |
Mar, 2025
(2 years from now) | |
| EP1294378A4 | NOVARTIS | Thrombopoietin Mimetics |
Mar, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7160870
(Pediatric) | NOVARTIS | Thrombopoietin mimetics |
May, 2023
(7 months from now) | |
| US7795293 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
May, 2023
(7 months from now) | |
|
US7795293
(Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Nov, 2023
(1 year, 1 month from now) | |
|
US7547719
(Pediatric) | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jan, 2026
(3 years from now) | |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
Treatment: Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy
Dosage: FOR SUSPENSION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 12.5MG ACID/PACKET | FOR SUSPENSION;ORAL | Prescription |
| EQ 25MG ACID/PACKET | FOR SUSPENSION;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.